U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07058779) titled 'Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects' on May 26.
Brief Summary: This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose SSS55 injection in healthy individuals.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Safety Issues
Intervention:
DRUG: SSS55
SSS55 is an injection targeting complement C3b
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Published by HT Digital Cont...